Acute Respiratory Distress Syndrome Market

In 2017, the total incident population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM was 7,99,872, out of all the incidence cases in seven major markets, the US accounts for about 4,95,655 cases.

The market size of Acute Respiratory Distress Syndrome (ARDS) in the 7MM is expected to grow at a CAGR of 9.55% during the study period (2017-2030).

The key pharma players in the Acute Respiratory Distress Syndrome (ARDS) market includes Faron Pharmaceuticals, Biomarck Pharmaceuticals, Athersys, Inc, Alexion Pharmaceuticals, Apeptico, and many others.

For more detailed information on Acute Respiratory Distress Syndrome (ARDS) Market, visit:
https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market